CSF2 and neoplasm: The drug product contains modified HSV-1 with deletion of two non-essential genes (ICP34.5, replaced by GM-CSF gene, and ICP47) that results in decreased neurotoxicity, enhanced tumor-specific cell lysis, and increased immune response at the tumor site.8